Filing Flows

Filing Flows › 8-K events › Cumberland Pharmaceuticals

Cumberland Pharmaceuticals: regulation fd disclosure

Form 8-K filed Oct 26, 2026 · items 7.01, 8.01

What the filing says

On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban product candidate, which is in development as a potential treatment for the cardiom

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Cumberland Pharmaceuticals at a glance

Latest quarterQ2 2026
Revenue$8.8M
Revenue Y/Y-19%
Operating margin-35.9%
IndustryPharmaceutical Preparations

Cumberland Pharmaceuticals, Q2 2026: revenue $8.8M (-19% year over year), operating margin -35.9%. The chart follows the revenue to costs, profit and cash.

Cumberland Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.